Morten Graugaard Døssing

Director at Muna Therapeutics

Morten joined Novo Holdings in 2016 and serves as Partner at Novo Seeds where he leads new company formation.

In addition to Muna Therapeutics, Morten has been instrumental in the creation of Hoba Therapeutics, HyperBio and Syndesi Therapeutics and also serves on the Board of Acesion Pharma, Avilex Pharma, NMD Pharma, Precirix, and STipe Therapeutics.

Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments including the acquisition of orphan neurology company Chelsea Therapeutics for 658M USD and a 1.8Bn USD alliance with Otsuka Pharmaceuticals.

Morten holds an MSc in Human Biology from the University of Copenhagen.


Org chart

This person is not in the org chart